NDAOPHTHALMICSOLUTION
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
1
Data completeness
5/8 — Partial
OMLONTI (omidenepag isopropyl) by ExThera Medical is ep2 receptor agonist which decreases intraocular pressure (iop). Approved for elevated intraocular pressure (iop) in patients with open-angle glaucoma, ocular hypertension, hypertension. First approved in 2022.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OMLONTI (omidenepag isopropyl) is an EP2 receptor agonist ophthalmic solution approved in September 2022 for reducing elevated intraocular pressure in open-angle glaucoma and ocular hypertension. It works by decreasing IOP through EP2 receptor activation, addressing a major risk factor for optic nerve damage and visual field loss.
Peak13.2 years to LOE
Early-stage specialty ophthalmic asset in peak lifecycle phase with 13+ years of patent protection, signaling sustained market presence and multi-functional team engagement.
Mechanism of Action
EP2 receptor agonist which decreases intraocular pressure (IOP). The exact mechanism of action is unknown at this time. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the greater the likelihood of optic nerve damage and visual field loss.
Worked on OMLONTI at ExThera Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.